Frontotemporal Dementia (FTD) drugs in development, 2024

GlobalData tracks 119 drugs in development for Frontotemporal Dementia (FTD) by 92 companies/universities/institutes. The top development phase for Frontotemporal Dementia (FTD) is preclinical, with 66 drugs in that stage.

Filament Health Enters Licensing Agreement With Reset Pharma | Psychedelic Invest

Reset Pharma has licensed Filament’s botanical psilocybin drug candidate for a phase 2 clinical trial studying demoralization syndrome Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE:

August 31, 2023

Pfizer’s first-ever bispecific antibody Elrexfio holds promise in multiple myeloma

Elrexfio’s higher dosage and limited trials may hinder its ability to rival Tecvayli. Credit: Kateryna Kon via Shutterstock. The US Food and Drug Administration’s recent

August 25, 2023

Numinus Wellness Announces Voting Results From its Annual General Meeting of Shareholders | Psychedelic Invest

VANCOUVER, BC, May 31, 2024 /PRNewswire/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments

June 3, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.